The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma

A 6-month randomized controlled study

Sally Wenzel, William Busse, William Calhoun, Reynold Panettieri, Mark Peters-Golden, Louise Dube, Karen Walton-Bowen, Heidy Russell, Judith Harris

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo). Sustained improvements in AM and PM peak expiratory flow (PEF) were observed in the zileuton CR group compared to placebo. The adverse event profile was similar in the two treatment groups. Eleven patients (1.8%) receiving zileuton CR and 2 (0.7%) receiving placebo experienced elevations of alanine aminotransferase (ALT) ≥ 3X the upper limit of normal (ULN). These elevations typically occurred (81.8%) during the first 3 months of exposure and most resolved within 21 days after discontinuation.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalJournal of Asthma
Volume44
Issue number4
DOIs
StatePublished - May 2007

Fingerprint

zileuton
Tablets
Asthma
Safety
Placebos
Therapeutics
Alanine Transaminase

Keywords

  • Adjunctive therapy
  • Asthma
  • Controlled-release
  • Zileuton

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma : A 6-month randomized controlled study. / Wenzel, Sally; Busse, William; Calhoun, William; Panettieri, Reynold; Peters-Golden, Mark; Dube, Louise; Walton-Bowen, Karen; Russell, Heidy; Harris, Judith.

In: Journal of Asthma, Vol. 44, No. 4, 05.2007, p. 305-310.

Research output: Contribution to journalArticle

Wenzel, Sally ; Busse, William ; Calhoun, William ; Panettieri, Reynold ; Peters-Golden, Mark ; Dube, Louise ; Walton-Bowen, Karen ; Russell, Heidy ; Harris, Judith. / The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma : A 6-month randomized controlled study. In: Journal of Asthma. 2007 ; Vol. 44, No. 4. pp. 305-310.
@article{aba705d6e24742cc828df101a53e7f8d,
title = "The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: A 6-month randomized controlled study",
abstract = "This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo). Sustained improvements in AM and PM peak expiratory flow (PEF) were observed in the zileuton CR group compared to placebo. The adverse event profile was similar in the two treatment groups. Eleven patients (1.8{\%}) receiving zileuton CR and 2 (0.7{\%}) receiving placebo experienced elevations of alanine aminotransferase (ALT) ≥ 3X the upper limit of normal (ULN). These elevations typically occurred (81.8{\%}) during the first 3 months of exposure and most resolved within 21 days after discontinuation.",
keywords = "Adjunctive therapy, Asthma, Controlled-release, Zileuton",
author = "Sally Wenzel and William Busse and William Calhoun and Reynold Panettieri and Mark Peters-Golden and Louise Dube and Karen Walton-Bowen and Heidy Russell and Judith Harris",
year = "2007",
month = "5",
doi = "10.1080/02770900701344199",
language = "English (US)",
volume = "44",
pages = "305--310",
journal = "Journal of Asthma",
issn = "0277-0903",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma

T2 - A 6-month randomized controlled study

AU - Wenzel, Sally

AU - Busse, William

AU - Calhoun, William

AU - Panettieri, Reynold

AU - Peters-Golden, Mark

AU - Dube, Louise

AU - Walton-Bowen, Karen

AU - Russell, Heidy

AU - Harris, Judith

PY - 2007/5

Y1 - 2007/5

N2 - This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo). Sustained improvements in AM and PM peak expiratory flow (PEF) were observed in the zileuton CR group compared to placebo. The adverse event profile was similar in the two treatment groups. Eleven patients (1.8%) receiving zileuton CR and 2 (0.7%) receiving placebo experienced elevations of alanine aminotransferase (ALT) ≥ 3X the upper limit of normal (ULN). These elevations typically occurred (81.8%) during the first 3 months of exposure and most resolved within 21 days after discontinuation.

AB - This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo). Sustained improvements in AM and PM peak expiratory flow (PEF) were observed in the zileuton CR group compared to placebo. The adverse event profile was similar in the two treatment groups. Eleven patients (1.8%) receiving zileuton CR and 2 (0.7%) receiving placebo experienced elevations of alanine aminotransferase (ALT) ≥ 3X the upper limit of normal (ULN). These elevations typically occurred (81.8%) during the first 3 months of exposure and most resolved within 21 days after discontinuation.

KW - Adjunctive therapy

KW - Asthma

KW - Controlled-release

KW - Zileuton

UR - http://www.scopus.com/inward/record.url?scp=34249747837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249747837&partnerID=8YFLogxK

U2 - 10.1080/02770900701344199

DO - 10.1080/02770900701344199

M3 - Article

VL - 44

SP - 305

EP - 310

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

IS - 4

ER -